Scientific leadership behind NETOsys.

Jonathan D. Spicer is a Canadian thoracic surgeon, clinician-scientist, and academic leader specializing in lung cancer and translational research. He is based at McGill University and the Research Institute of the McGill University Health Centre, where he plays a key role in advancing precision oncology and immunotherapy strategies.

Dr. Spicer's clinical work focuses on thoracic oncology, particularly the surgical management of lung cancer and other chest malignancies. As a researcher, he leads a multidisciplinary lab investigating tumor immunology, with a strong emphasis on the role of the tumor microenvironment, neutrophils, and mechanisms such as neutrophil extracellular traps (NETs) in cancer progression and therapeutic resistance.

He is also actively involved in clinical trials, contributing to the development of innovative treatments including immunotherapies and combination strategies for lung cancer. Through collaborations across academia and industry, Dr. Spicer has helped translate laboratory discoveries into early-phase clinical studies.

In addition to his research and clinical duties, Dr. Spicer is recognized for mentorship and leadership in academic medicine, training the next generation of surgeons and scientists. His contributions have positioned him as a prominent figure in thoracic oncology and translational cancer research in Canada and internationally.

Jonathan Cools-Lartigue is a clinician-scientist and academic leader recognized for his contributions to translational research at the intersection of cancer biology and immunology. Trained in surgery and deeply engaged in laboratory-based discovery, his work focuses on understanding how the tumor microenvironment, particularly neutrophils and their extracellular traps (NETs), influences cancer progression, metastasis, and therapeutic resistance.

His research has helped advance the emerging field of NET-targeted diagnostics and therapeutics, with implications across oncology and inflammatory diseases. In addition to his scientific work, Dr. Cools-Lartigue is known for his commitment to bridging bench-to-bedside innovation.

He has led multidisciplinary teams, secured competitive research funding, and contributed to the development of novel biomarker strategies aimed at improving patient outcomes. His academic output includes high-impact publications and collaborations with international research groups.

Beyond the lab and clinic, he is a dedicated mentor and educator, actively involved in training the next generation of physicians and scientists. His work reflects a broader vision of integrating precision medicine with immunological insights to transform how complex diseases are diagnosed and treated.

Roni F. Rayes is an expert in tumor immunology, with more than 10 years of work specifically focused on developing novel preclinical models for the study of lung cancer and neutrophil biology. His background combines scientific leadership, innovation, and strategic development.

Dr. Rayes is recognized for analytical thinking, creativity, and leadership, with a collaborative and results-oriented approach to building multidisciplinary teams and moving complex initiatives forward. His work has consistently linked scientific discovery with real-world application.

Throughout his career, he has contributed to research programs, supported innovation efforts, and helped shape projects that bridge laboratory insight with translational relevance. His perspective brings operational rigor and forward-looking company building to the NETOsys platform.

His work reflects a continued commitment to excellence, intellectual curiosity, and the pursuit of meaningful outcomes in cancer biology, neutrophil research, and emerging diagnostic opportunities.

Martin Wong is a finance executive and investment banker with extensive experience in capital markets, corporate finance, and strategic advisory work. As CFO of NETOsys, he supports financial planning, governance, financing strategy, and investor-facing preparation as the company advances its NET-focused diagnostic platform.

His background includes complex financing transactions, IPO-related work, debt restructuring, and corporate advisory mandates across public and private companies. This experience gives NETOsys practical financial leadership for evaluating capital needs, structuring opportunities, and communicating a credible business case around scientific and clinical milestones.

Mr. Wong has held senior leadership roles in investment banking and has worked with companies across healthcare, life sciences, and other innovation-driven sectors. He brings a broad network across medical, life science, public company, and philanthropic organizations, with experience supporting growth, restructuring, and strategic transactions.

At NETOsys, Mr. Wong contributes financial discipline and capital markets perspective to company building. His work helps align financial strategy, investor communication, and partnership opportunities with the company's diagnostic development priorities.

Benjamin Ralph is an immunology and molecular biology scientist who helps turn antibody-based research programs into disciplined, executable R&D plans.

Dr. Ralph's McGill doctoral training and postdoctoral work provide depth in immune response biology, host-pathogen models, and experimental design. He applies that foundation to evaluate scientific priorities, identify technical risks, and guide assay and workflow decisions.

Across roles at McGill, the RI-MUHC, IRIC, and MediMabs Antibodies, he contributed to multidisciplinary research programs and coordinated project goals with academic and industry partners. His background combines hands-on scientific execution with project alignment, knowledge transfer, and workflow improvement.

At NETOsys, Dr. Ralph brings practical R&D judgment to NET-focused diagnostic development. His experience helps connect scientific strategy, experimental execution, and partner communication as the company advances antibody-based diagnostic opportunities.